Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma

Table 1 Physiological characteristics of hepatocellular carcinoma patients (n = 162)

	n (%)
Sex
Female	15 (9.3)
Male	147 (90.7)
Age (yr)
< 48	77 (47.5)
≥ 48	85 (52.5)
HBV infection1
-	21 (13.0)
+	140 (86.4)
HCV infection
-	158 (97.5)
+	4 (2.5)
GGT (U/L)2
< 50	45 (27.8)
50-99	48 (29.6)
≥ 100	67 (41.4)
AFP (ng/mL)
< 20	53 (32.7)
20-399	45 (27.8)
≥ 400	64 (39.5)
Tumor size (cm)
< 5	53 (32.7)
≥ 5	109 (67.3)
Ascites3
-	148 (91.4)
+	14 (8.6)
Cirrhosis
Total	19 (11.7)
Mild	80 (49.4)
Moderate	49 (30.2)
Severe	14 (8.6)
Edmondson grade
I	11 (6.8)
II	71 (43.8)
III	77 (47.5)
IV	3 (1.9)
TNM stage
I	106 (65.4)
II	7 (4.3)
III	49 (30.3)
G-1666A genotype
AA	55 (34.0)
AG	89 (54.9)
GG	18 (11.1)

¹(-) absence, (+) presence, one case unconfirmed;

²Two cases unconfirmed;

³(-) absence, (+) presence. HBV: Hepatitis B virus; HCV: Hepatitis C virus; GGT: γ-glutamyl transpeptidase; AFP: α-fetoprotein.

Table 2 Determination of prognostic factors for disease-free survival and overall survival of patients with hepatocellular carcinoma, by univariate analysis (n = 162)

Variable	DFS		OS
	HR (95% CI)	Pa	HR (95% CI)	Pa
Sex
Female	1		1
Male	4.231 (1.035-17.299)	0.045	7.522 (1.041-54.337)	0.045
GGT (U/L)1
< 50	1		1
50-99	2.064 (0.920-4.632)	0.079	1.771 (0.734-4.275)	0.203
≥ 100	3.639 (1.761-7.519)	0.001	3.728 (1.734-8.014)	0.001
AFP (ng/mL)
< 20	1		1
20-399	1.852 (0.954-3.595)	0.068	2.004 (0.989-4.061)	0.054
≥ 400	1.997 (1.070-3.725)	0.030	2.102 (1.079-4.094)	0.029
Tumor size (cm)
< 5	1		1
≥ 5	2.230 (1.233-4.030)	0.008	2.089 (1.126-3.875)	0.019
Ascites2
-	1		1
+	2.562 (1.301-5.044)	0.007	2.81 (1.375-5.741)	0.005
Cirrhosis
No	1		1
Mild	2.005 (0.710-5.661)	0.189	2.505 (0.763-8.225)	0.130
Moderate	1.832 (0.623-5.387)	0.271	2.287 (0.670-7.806)	0.187
Severe	3.230 (0.993-10.505)	0.051	4.796 (1.297-17.738)	0.019
TNM stage
I	1		1
II + III	3.165 (1.940-5.163)	< 0.001	3.424 (2.038-5.752)	< 0.001
Genotypes
AA	1		1
AG	0.830 (0.479-1.439)	0.507	0.818 (0.463-1.447)	0.490
GG	1.988 (0.982-4.024)	0.056	1.491 (0.682-3.258)	0.317
AA + AG	1		1
GG	2.223 (1.185-4.172)	0.013	1.678 (0.822-3.422)	0.155

^aHazard ratio (HR) and P values were calculated using univariate Cox regression. P < 0.05 was considered to indicate statistical significance;

¹Two cases unconfirmed;

²(+) presence, (-) absence. DFS: Disease-free survival; OS: Overall survival; CI: Confidence interval; GGT: γ-glutamyl transpeptidase; AFP: α-fetoprotein.

Table 3 Multivariate analysis for prognostic value of multidrug resistance related protein-1 G-1666A polymorphism in patients with hepatocellular carcinoma

Genotypes	DFS1		OS2
	HR (95% CI)	Pa	HR (95% CI)	Pa
All (n = 162)
AA+AG	1
GG	3.067 (1.587-5.952)	0.001
Men (n = 147)
AA + AG	1		1
GG	3.154 (1.604-6.201)	0.001	3.342 (1.474-7.576)	0.004

^aHazard ratio (HR) and P values were calculated using multivariate Cox regression. P < 0.05 was considered to indicate statistical significance;

¹Multivariate analysis of disease-free survival (DFS) in all patients was adjusted for sex, γ-glutamyl transpeptidase (GGT), α-fetoprotein (AFP), tumor size, ascites, and TNM stage; in male patients, it was adjusted for GGT, tumor size, and TNM stage;

²Multivariate analysis of OS in male patients was adjusted for GGT, tumor size, ascites, cirrhosis, and TNM stage. OS: Overall survival; CI: Confidence interval.